Paragon Wealth Strategies, LLC Monopar Therapeutics Call Options Transaction History

Paragon Wealth Strategies, LLC

  • $346 Million
  • Q4 2023

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About Monopar Therapeutics

MNPR Quotes by TradingView
  • Ticker MNPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,725,800
  • Market Cap $617M
  • Description
  • Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...
More about MNPR
Track This Portfolio

Track Paragon Wealth Strategies, LLC Portfolio

Follow Paragon Wealth Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paragon Wealth Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Paragon Wealth Strategies, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email